PHARMACOKINETICS AND PHARMACODYNAMICS OF ENAVOGLIFLOZIN, AN SGLT-2 INHIBITOR, IN TYPE 2 DIABETES PATIENTS WITH IMPAIRED RENAL FUNCTION

被引：0
|
作者：
Kim, Y. [1 ]
Huh, K. [1 ]
Jeong, S. [2 ]
Cho, J. [3 ]
Huh, W. [3 ]
Shin, Y. [4 ]
Chung, J. [1 ]
机构：
[1] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[2] Chungbuk Natl Univ Hosp, Cheongju, South Korea
[3] Daewoong Pharmaceut Co, Seoul, South Korea
[4] iN Therapeut, Yonginsi, South Korea
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-015
引用
收藏
页码：S51 / S51
页数：1
相关论文
共 50 条
  • [1] An SGLT-2 inhibitor reverses impaired ventricular repolarisation in patients with type 2 diabetes
    Sato, T.
    Miki, T.
    Ohnishi, H.
    Yamashita, T.
    Takada, A.
    Yano, T.
    Tanno, M.
    Tsuchida, A.
    Miura, T.
    DIABETOLOGIA, 2017, 60 : S424 - S425
  • [2] The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes
    Jeong, Sae Im
    Ban, Mu Seong
    Hwang, Jun-Gi
    Park, Min-Kyu
    Lim, Soo
    Kim, Sejoong
    Kwon, Soon Kil
    Kim, Yoonjin
    Cho, Jae Min
    Na, Jae Jin
    Huh, Wan
    Chung, Jae-Yong
    DIABETES OBESITY & METABOLISM, 2024, 26 (07): : 2588 - 2597
  • [3] Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus
    Ikeda, Sachiya
    Takano, Yasuki
    Schwab, Dietmar
    Portron, Agnes
    Kasahara-Ito, Nahoko
    Saito, Tomohisa
    Iida, Satofumi
    DRUG RESEARCH, 2019, 69 (06) : 314 - 322
  • [4] Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment
    Samukawa, Yoshishige
    Haneda, Masakazu
    Seino, Yutaka
    Sasaki, Takashi
    Fukatsu, Atsushi
    Kubo, Yusuke
    Sato, Yuri
    Sakai, Soichi
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (08): : 820 - 828
  • [5] Effects of the SGLT-2 inhibitor empagliflozin on vascular function and central haemodynamics in patients with type 2 diabetes
    Schmieder, R. E.
    Striepe, K.
    Jumar, A.
    Karg, M. V.
    Kannenkeril, D.
    Schneider, M. P.
    Ott, C.
    DIABETOLOGIA, 2017, 60 : S417 - S417
  • [6] SGLT-2 and SGLT-1 expression in renal tissue of patients with type 2 diabetes
    Solini, A.
    Rossi, C.
    Proietti, A.
    Ferrannini, E.
    DIABETOLOGIA, 2016, 59 : S351 - S351
  • [7] 5.1: Effects of the SGLT-2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients with Type 2 Diabetes
    Christian Ott
    Kristina Striepe
    Agnes Jumar
    Marina Karg
    Markus Schneider
    Dennis Kannenkeril
    Roland Schmieder
    Artery Research, 2017, 20 (1) : 58 - 58
  • [8] Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world
    Song, Rongjing
    Hou, Qiaoyu
    Zhang, Xiuying
    Zhao, Wei
    Liu, Gang
    Li, Meng
    Zhang, Xiaohong
    Ji, Linong
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [9] Short-term Renoprotective Effect of SGLT-2 Inhibitor for Renal Function and Albuminuria in Type 2 Diabetes: a Retrospective Study
    Mitsunobu Kubota
    Eri Shiroyama
    Kanako Tanaka
    Yoko Yoshii
    SN Comprehensive Clinical Medicine, 2021, 3 (1) : 201 - 209
  • [10] Type 2 Diabetes with or without renal Impairment SGLT-2 Inhibitor with cardio- and nephroprotective Effect
    Wiehl, Martin
    DIABETES STOFFWECHSEL UND HERZ, 2022, 31 (06): : 355 - 355
12345